JPMorgan Chase & Co. Buys Shares of 34,013 CeriBell (NASDAQ:CBLL)

JPMorgan Chase & Co. purchased a new position in CeriBell (NASDAQ:CBLL - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 34,013 shares of the company's stock, valued at approximately $880,000. JPMorgan Chase & Co. owned about 0.09% of CeriBell at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the company. PNC Financial Services Group Inc. purchased a new stake in CeriBell during the 4th quarter valued at about $47,000. Corebridge Financial Inc. purchased a new stake in CeriBell in the fourth quarter valued at approximately $158,000. Rhumbline Advisers purchased a new stake in CeriBell in the fourth quarter valued at approximately $320,000. Bank of New York Mellon Corp acquired a new position in CeriBell in the 4th quarter worth approximately $628,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in CeriBell during the 4th quarter worth approximately $2,500,000.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on CBLL shares. LADENBURG THALM/SH SH began coverage on shares of CeriBell in a research note on Friday, April 4th. They issued a "buy" rating and a $32.00 price objective on the stock. Canaccord Genuity Group reissued a "buy" rating and issued a $33.00 price objective on shares of CeriBell in a report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $32.50.

CeriBell Stock Performance

CBLL traded up $0.19 on Thursday, reaching $16.28. The stock had a trading volume of 219,582 shares, compared to its average volume of 271,272. The company has a 50-day moving average price of $19.22. CeriBell has a 12-month low of $10.01 and a 12-month high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The company had revenue of $18.53 million during the quarter, compared to the consensus estimate of $17.55 million. On average, equities research analysts forecast that CeriBell will post -2.46 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Xingjuan Chao sold 5,700 shares of CeriBell stock in a transaction dated Thursday, April 17th. The stock was sold at an average price of $15.02, for a total value of $85,614.00. Following the sale, the chief executive officer now directly owns 746,451 shares in the company, valued at approximately $11,211,694.02. The trade was a 0.76 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 24,700 shares of company stock worth $372,434.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.